絞り込み

16555

広告

Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

著者 Lo C , Toyama T , Wang Y , Lin J , Hirakawa Y , Jun M , Cass A , Hawley CM , Pilmore H , Badve SV , Perkovic V , Zoungas S
Cochrane Database Syst Rev.2018 Sep 24 ; 9():CD011798.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (26view , 0users)

Full Text Sources

Miscellaneous

Diabetes is the commonest cause of chronic kidney disease (CKD). Both conditions commonly co-exist. Glucometabolic changes and concurrent dialysis in diabetes and CKD make glucose-lowering challenging, increasing the risk of hypoglycaemia. Glucose-lowering agents have been mainly studied in people with near-normal kidney function. It is important to characterise existing knowledge of glucose-lowering agents in CKD to guide treatment.
PMID: 30246878 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード